Multiple Outcomes Significantly Improved


Continue Reading

With the marker implanted, radiation oncologists have a much easier time decreasing volumes and administering accelerated radiation doses, resulting in a shorter overall course. Most of my BCS patients now undergo radiation treatment for only 3 to 4 weeks as opposed to 6 weeks. “This makes a big difference,” Dr Cross said. “The next step will be only 5 to 7 days; that will be terrific as well as a big economic benefit to the health care system.”

Dr Cross concluded, “[the BioZorb marker] is honestly the first time I have used a technology that benefits the patient in a number of different ways along the course of their care pathway, with positive effects on surgical outcome, the radiation treatments, and the long-term follow up. It is this unique ability of BioZorb that makes it a ‘game changer’ technology that I believe will one day soon become standard of care.”


Megan Garlapow is a medical writer based in Tempe, Arizona. 


References

1. Leonard KL, et al. Placement of the BioZorb® marker is associated with smaller irradiated tumor bed in patients receiving breast conserving therapy. Poster presentation at: 18th Annual Meeting of the American Society of Breast Surgeons; April 26-30, 2017; Las Vegas, NV.

2. Cross MJ, Jones S, Smith A, Young T. Impact of a 3D bioabsorbable implant on the rate of breast conserving surgery: review of 1,115 breast cancer patients in the private practice setting. Poster presentation at: 18th Annual Meeting of the American Society of Breast Surgeons; April 26-30, 2017; Las Vegas, NV.